Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
about
Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.A novel role for ATR/Rad3 in G1 phase.Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP-E2F1-DNA damage response pathway axis.WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapyInhibition of WEE1 Suppresses the Tumor Growth in Laryngeal Squamous Cell Carcinoma
P2860
Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combined inhibition of Wee1 an ...... DK activity and CDC45 loading.
@en
Combined inhibition of Wee1 an ...... DK activity and CDC45 loading.
@nl
type
label
Combined inhibition of Wee1 an ...... DK activity and CDC45 loading.
@en
Combined inhibition of Wee1 an ...... DK activity and CDC45 loading.
@nl
prefLabel
Combined inhibition of Wee1 an ...... DK activity and CDC45 loading.
@en
Combined inhibition of Wee1 an ...... DK activity and CDC45 loading.
@nl
P2093
P2860
P356
P1433
P1476
Combined inhibition of Wee1 an ...... DK activity and CDC45 loading.
@en
P2093
Christian Naucke
Grete Hasvold
Gro Elise Rødland
Mrinal Joel
Petras Juzenas
Randi G Syljuåsen
Sissel Hauge
Trond Stokke
P2860
P304
10966-10979
P356
10.18632/ONCOTARGET.14089
P407
P577
2016-12-22T00:00:00Z